The last year has seen a surge of investment in longevity biotech companies, driving more demand for reliable and fast methods to screen compounds for their ability to slow ageing. Magnitude Biosciences is in a great position to service this demand, as a contract research organisation (CRO) with rich expertise in this area and a portfolio of success stories of helping drug discovery biotechs get the data they need. New lab hires Alanna and Hannah are helping the team scale its capacity to meet this increased demand while maintaining the highest quality of scientific standards at industry-best levels of speed and efficiency.

Magnitude Biosciences Chief Executive David Weinkove commented: “I am delighted to welcome Alanna and Hannah to the team. We are catching the attention of the ageing drug discovery and health and wellness product fields, and enjoying working with more biotechs as repeat customers, as they narrow their search for the best drug candidates. Our new colleagues are already enabling us to work on even more exciting projects.”